US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

63.63

+0.07440.12%

Post-market: 63.50-0.1290-0.20%16:10 EDT

Volume:9K

Turnover:589.16K

Market Cap:274.88M

PE:20.81

High:63.63

Open:63.27

Low:62.99

Close:63.55

52wk High:64.10

52wk Low:39.10

Shares:4.32M

Float Shares:4.32M

Volume Ratio:0.27

T/O Rate:0.22%

Dividend:1.53

Dividend Rate:2.40%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Roivant Sciences Ltd : TD Cowen Raises Target Price to $50 from $41

THOMSON REUTERS

Dual Focus on Innovation and Global Expansion Drives Medical Device Sector Upgrades - ETF Tool Supports Recovery Opportunities

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bernstein Remains a Hold on Revolution Medicines (RVMD)

Roivant Sciences Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

Roivant Sciences' Fiscal Q1 Net Loss Narrows, Revenue Declines

MT Newswires Live

Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million

Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Benzinga Earnings

Roivant Unit Priovant Begins Phase 3 Beacon+ Trial of Brepocitinib in Cutaneous Sarcoidosis

Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million

Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million

Roivant Sciences - Brepocitinib Nda Approval and Launch in Dermatomyositis Expected by End of September 2026

THOMSON REUTERS

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PTH/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":63.629,"timestamp":1787774400000,"preClose":63.5546,"halted":0,"volume":9295,"hourTrading":{"tag":"盘后","latestPrice":63.5,"preClose":63.629,"latestTime":"16:10 EDT","volume":19,"amount":1212.3165,"timestamp":1787775005417,"change":-0.129,"changeRate":-0.002027,"amplitude":0},"delay":0,"changeRate":0.0011706469712656068,"floatShares":4320000,"shares":4320000,"eps":3.057033,"marketStatus":"Closed","change":0.0744,"latestTime":"08-26 16:00:00 EDT","open":63.27,"high":63.629,"low":62.985,"amount":589164,"amplitude":0.010133,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787817600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":63.5546,"sharesOutstanding":2480000,"nav":63.56092,"aum":280939266.4,"dividendRate":0.023972,"bidAskSpread":0.002223,"preHourTrading":{"tag":"盘前","latestPrice":63.5546,"preClose":63.5546,"latestTime":"07:01 EDT","volume":1,"amount":63.5546,"timestamp":1787742068433,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":63.5,"preClose":63.629,"latestTime":"16:10 EDT","volume":19,"amount":1212.3165,"timestamp":1787775005417,"change":-0.129,"changeRate":-0.002027,"amplitude":0},"volumeRatio":0.26737,"impliedVol":0.0861,"impliedVolPercentile":0.2629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4320000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.26737,"shares":4320000,"dividePrice":1.5253,"high":63.629,"amplitude":0.010133,"preClose":63.5546,"low":62.985,"week52Low":39.1,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":63.629,"eps":3.057033,"divideRate":0.023972,"volume":9295,"delay":0,"ttmEps":3.057033,"open":63.27,"prevYearClose":49.701,"prevWeekClose":62.9761,"prevMonthClose":58.0963,"prevQuarterClose":59.76,"fiveDayClose":64.0724,"twentyDayClose":57.08,"sixtyDayClose":50.8485},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657718691","title":"Roivant Sciences Ltd : TD Cowen Raises Target Price to $50 from $41","url":"https://stock-news.laohu8.com/highlight/detail?id=2657718691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657718691?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:05","pubTimestamp":1786082707,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4440JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169655769","title":"Dual Focus on Innovation and Global Expansion Drives Medical Device Sector Upgrades - ETF Tool Supports Recovery Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1169655769","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169655769?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:42","pubTimestamp":1786063349,"startTime":"0","endTime":"0","summary":"The medical device sector, which has faced significant pressure in recent years, is now poised for a turning point. This shift is driven by a systemic optimization of healthcare industry policies,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","RSPH","CZA","MEDX","LCO","MDEV","GDOC","PTH","NIFE","09996","159883","HART","BK1583","IEIH","AGNG","LNGR","159898","BK1100","LGHT","REVS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652347","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652347?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:30","pubTimestamp":1786044629,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Opus Genetics (IRD) and Reg...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-283?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-283?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTH","ROIV","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658768","title":"Bernstein Remains a Hold on Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657658768?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:01","pubTimestamp":1786028493,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jeffrey Walch from Bernstein maintained a Hold rating on Revolution Medicines, with a price target of $151.00. Walc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-revolution-medicines-rvmd-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-revolution-medicines-rvmd-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE0009354923.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4139","IE0009355771.USD","IDNA","LU0889565916.HKD","PTH","LU0320765992.SGD","IE00BJT1NW94.SGD","BBH","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","RVMD","CANC","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632462","title":"Roivant Sciences Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632462","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632462?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023131,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd reports results for the quarter ended June 30 - Earnings SummaryRoivant Sciences LtdROIV.OQreported a quarterly adjusted loss of 26 cents per share for the quarter ended June 30, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632405","title":"Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632405","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632405?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023121,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. reports results for the quarter ended June 30 - Earnings SummaryImmunovant, Inc.IMVT.OQreported a quarterly adjusted loss of 75 cents per share for the quarter ended June 30, lower th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4585","BK4588","IMVT","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639266","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639266?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:10","pubTimestamp":1786018244,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revolution-medicines-rvmd-royalty-pharma-rprx-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revolution-medicines-rvmd-royalty-pharma-rprx-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4007","CANC","PTH","LU0128526141.USD","BBH","RVMD","IHE","LU0889565916.HKD","XBI","IE00BJJMRZ35.SGD","BK4137","IE0002141913.USD","RPRX","LU0320765992.SGD","URGN","XLV","LABU","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","BK4581","IDNA","IE0009355771.USD","BK4585","PBE","LU0109394709.USD","BK4588","HCSG","IE00B2B36J28.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163591","title":"Roivant Sciences' Fiscal Q1 Net Loss Narrows, Revenue Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163591?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:40","pubTimestamp":1786016421,"startTime":"0","endTime":"0","summary":"Roivant Sciences  reported a fiscal Q1 net loss Thursday of $0.26 per diluted share, narrowing from a loss of $0.33 per share a year earlier.Four analysts polled by FactSet expected a loss of $0.33 per share.Revenue for the quarter ended June 30 was $1.4 million, compared with $2.2 million a year earlier.Analysts expected $2.1 million.Shares of Roivant Sciences were up more than 1% premarket Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657335626","title":"Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657335626","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657335626?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015233,"startTime":"0","endTime":"0","summary":"Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 millionImmunovant posted a wider net loss of USD 153.2 million, or USD 0.75 a share, for the quarter ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnH5Br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","IMVT","BK4139","BK4588","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638786","title":"Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638786","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:12","pubTimestamp":1786014730,"startTime":"0","endTime":"0","summary":"Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60988265/roivant-sciences-q1-adj-eps-0-34-misses-0-32-estimate-sales-1-442m-miss-2-057m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657198638","title":"Roivant Unit Priovant Begins Phase 3 Beacon+ Trial of Brepocitinib in Cutaneous Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2657198638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657198638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:07","pubTimestamp":1786014437,"startTime":"0","endTime":"0","summary":"Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosisRoivant unit Priovant enrolled first patients in a Phase 3 trial of brepocitinib for cutaneous sarcoidosis, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL4GgQ86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638191","title":"Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638191","media":"Reuters","labels":["shareholding","policyRegulatory","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638191?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:07","pubTimestamp":1786014430,"startTime":"0","endTime":"0","summary":"Roivant Q1 FY27 net loss widens to $290.61 million; revenue slips to $1.44 millionRoivant posted a GAAP net loss of USD 290.61 million, widening from USD 273.91 million a year earlier; GAAP loss per s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9Ngwhl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","BK4548","MRNY","MRNX","GNOM","IDNA","PTH","BK4007","BK4532","WDNA","BK4551","BK4139","LGHT","BK4501","BK4534","MRNA","BK4588","ROIV","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638810","title":"Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638810","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638810?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014062,"startTime":"0","endTime":"0","summary":"BRIEF-Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 MillionAug 06  - Roivant Sciences Q1 revenue USD 1.442 million.Q1 net income USD -290.606 millionQ1 pretax profit USD -294.564 million vs. IBES estimate USD -243.7 millionQ1 basic EPS USD -0.26Q1 income from operations USD -365.993 million vs. IBES estimate USD -306.8 millionQ1 operating expenses USD 367.827 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXNPHVMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633601","title":"Roivant Sciences - Brepocitinib Nda Approval and Launch in Dermatomyositis Expected by End of September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633601?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA7TZ9FK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657899596","title":"Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236","url":"https://stock-news.laohu8.com/highlight/detail?id=2657899596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657899596?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:10","pubTimestamp":1786007401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44313L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","IE00BFTCPJ56.SGD","PTH","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","BBH","IE0009354923.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","CANC","BK4139","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571976","title":"Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571976?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:01","pubTimestamp":1785967310,"startTime":"0","endTime":"0","summary":"Revolution Medicines publishes corporate deck outlining RAS(ON) inhibitor pipeline targeting RAS-driven cancersRevolution Medicines highlighted Phase 3 RASolute 302 data in previously treated metastat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL65Wkg4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","RVMD","CANC","IE00B4R5TH58.HKD","PTH","IE0002141913.USD","BK4139","IE0009354923.USD","LU0889565916.HKD","IDNA","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","LFSC","BK4588","BK4196","BK4585","BK4551","EKG","FFOX","GDOC","GH","LU0889565916.HKD","GNOM","PTH","HELX","LU0109394709.USD","LU0320765992.SGD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657576322","title":"Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657576322","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657576322?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:01","pubTimestamp":1785963706,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. reports results for the quarter ended June 30 - Earnings SummaryRevolution Medicines, Inc.RVMD.OQreported a quarterly adjusted loss of $3.06 per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4423HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","IE00BJJMRZ35.SGD","IDNA","IE00BJT1NW94.SGD","PTH","RVMD","IE00B2B36J28.USD","CANC","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4139","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE0002141913.USD","LU0889565916.HKD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657057882","title":"Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657057882","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657057882?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:17","pubTimestamp":1785961029,"startTime":"0","endTime":"0","summary":"Revolution Medicines Q2 FY26 net loss widens to $644.4 million; R&D expenses rise to $394.9 millionRevolution Medicines posted a GAAP net loss of $644.4 million for Q2 2026, widening from a $247.8 mil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL46m7gf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","PTH","IE00BKPKM429.USD","IE0009355771.USD","RPRX","LU0889565916.HKD","BK4112","BCDF","CANC","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","NDAQ","LU0320765992.SGD","PBE","BBH","IE00B2B36J28.USD","IE00BN0W2W23.USD","SG9999014039.USD","BK4007","IHE","LU0314104364.USD","SG9999014013.SGD","BK4139","IE0002141913.USD","SG9999014021.USD","IDNA","IE0009354923.USD","SG9999014005.SGD","BK4585","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657527610","title":"Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2657527610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657527610?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:02","pubTimestamp":1785960120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA9FY8WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IDNA","BBH","CANC","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","PTH","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}